Stereotactic radiosurgery with whole brain radiotherapy combined with bevacizumab in the treatment of brain metastases from NSCLC

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cufer T, Knez L. Update on systemic therapy of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2014; 14(10):1189–1203.
   PubMed Web of Science ®Google Scholar
• Kaal EC, Niël CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol. 2005; 4(5):289–298.
   PubMed Web of Science ®Google Scholar
• Liang P, Wang Y-D, Wei Z-M, et al. Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis. Open Med (Wars). 2020; 15(1):589–597.
   PubMedGoogle Scholar
• Pan H-C, Sun M-H, Chen CC-C, et al. Neuroimaging and quality-of-life outcomes in patients with brain metastasis and peritumoral edema who undergo Gamma Knife surgery. SUP. 2008; 109(Supplement):90–98.
   Web of Science ®Google Scholar
• Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep. 2015; 17(6):26.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang E, Pan L, et al. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. J Neurooncol. 2014; 119(2) :369–376.
   PubMed Web of Science ®Google Scholar
• Besse B, Le Moulec S, Mazières J, et al. Bevacizumab in patients with nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin Cancer Res. 2015; 21(8) :1896–1903.
   PubMed Web of Science ®Google Scholar
• Tang N, Guo J, Zhang Q, et al. Greater efficacy of chemotherapy plus bevacizumab compared to chemo-and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget. 2016; 7(3):3635–3644.
   PubMedGoogle Scholar
• Kalkanis SN, Linskey ME. Evidence-based clinical practice parameter guidelines for the treatment of patients with metastatic brain tumors: introduction. J Neurooncol. 2010; 96(1):7–10.
   PubMed Web of Science ®Google Scholar
• Masuda E, et al. Palliative procedures in lung cancer. In Seminars in interventional radiology. Leipzig, Germany: Thieme Medical Publishers; 2013.
   Google Scholar
• Gong L, Cumpian AM, Caetano MS, et al. Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer. 2013; 12(1):154.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber H-P, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3(5):391–400.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang J-J, Tu H-Y, et al. Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases. Int J Clin Oncol. 2020; 25(2):267–273.
   PubMed Web of Science ®Google Scholar
• Caffo M, Barresi V, Caruso G, et al. Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci. 2013; 14(1):2135–2174.
   PubMed Web of Science ®Google Scholar
• Seoane J, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Mol Oncol. 2014; 8(6):1120–1131.
   PubMed Web of Science ®Google Scholar
• Yang L, Chen C-J, Guo X-L, et al. Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis. J Neurooncol. 2018; 137(1):49–56.
   PubMed Web of Science ®Google Scholar
• Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005; 65(3) :671–680.
   PubMed Web of Science ®Google Scholar
• Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010; 16(1):269–278.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases . J Clin Oncol. 2009; 27(31):5255–5261.
   PubMed Web of Science ®Google Scholar
• Levy C, et al. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol. 2014; 25(12) :2351–2356.
   PubMed Web of Science ®Google Scholar
• Yang RF, Yu B, Zhang RQ, et al. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer. Braz J Med Biol Res. 2018; 51(1):e6073–e6073.
   Web of Science ®Google Scholar
• Guinde J, Carron R, Tomasini P, et al. Bevacizumab Plus Radiosurgery for Nonsquamous Non–Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?World Neurosurgery. 2017; 107:1047.e1–1047.e4.
   PubMed Web of Science ®Google Scholar
• Chira C, Jacob J, Derhem N, et al. Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy. J Neurooncol. 2011; 105(2):401–408.
   PubMed Web of Science ®Google Scholar
• Lou E, Sperduto PW. Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?Ann Trans Med. 2016; 4(2):36.
   Web of Science ®Google Scholar
• McTyre E, Scott J, Chinnaiyan P. Whole brain radiotherapy for brain metastasis. Surg Neurol Int. 2013;4(Suppl 4):S236–S244.
   PubMedGoogle Scholar
• Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015; 33(30):3475–3484.
   PubMed Web of Science ®Google Scholar
• Aoyama H, Tago M, Shirato H. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol. 2015; 1(4):457–464.
   PubMed Web of Science ®Google Scholar
• Churilla TM, Handorf E, Collette S, et al. Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. Ann Oncol. 2017; 28(10):2588–2594.
   PubMed Web of Science ®Google Scholar
• Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037–1044.
   PubMed Web of Science ®Google Scholar
• Yomo S, Hayashi M. Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report. J Neurooncol. 2016; 127(1):119–126.
   PubMed Web of Science ®Google Scholar
• Oosting SF, van Asselt SJ, Brouwers AH, et al. 89Zr-bevacizumab PET visualizes disease manifestations in patients with von Hippel-Lindau Disease. J Nucl Med. 2016; 57(8):1244–1250.
   PubMed Web of Science ®Google Scholar
• Masuda C, Sugimoto M, Wakita D, et al. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. Clin Exp Metastasis. 2020; 37(1):199–207.
   PubMed Web of Science ®Google Scholar
• Chikaishi Y, Kanayama M, Taira A, et al. Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer. Ann Transl Med. 2018; 6(20):401–401.
   PubMed Web of Science ®Google Scholar